Tax

Deferred Tax

Vertex Pharmaceuticals Deferred Tax remained flat by 0.0% to -$127.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 46.4%, from -$87.20M to -$127.70M. Over 2 years (FY 2023 to FY 2025), Deferred Tax shows relatively stable performance with a -2.4% CAGR.

Analysis

StatementIncome Statement
SectionTax
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2015
Last reportedQ3 2025

How to read this metric

A deferred tax expense indicates future tax liabilities, while a deferred tax benefit indicates future tax savings.

Detailed definition

Represents the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial...

Peer comparison

Standard tax accounting metric; comparable to 'deferred tax provision' at peer firms.

Metric ID: is_msft_deferred_income_tax_expense_benefit

Historical Data

3 years
 FY'23FY'24FY'25
Value-$536.50M-$348.80M-$510.80M
YoY Change—+35.0%-46.4%
Range-$536.50M – -$348.80M
CAGR-2.4%
Avg YoY Growth-5.7%
Median YoY Growth-5.7%

Deferred Tax at Other Companies

GLW
CorningGLWView metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's deferred tax?
Vertex Pharmaceuticals (VRTX) reported deferred tax of -$127.70M in Q4 2025.
How has Vertex Pharmaceuticals's deferred tax changed year-over-year?
Vertex Pharmaceuticals's deferred tax decreased by 46.4% year-over-year, from -$87.20M to -$127.70M.
What is the long-term trend for Vertex Pharmaceuticals's deferred tax?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred tax has grown at a -2.4% compound annual growth rate (CAGR), from -$536.50M to -$510.80M.
What does deferred tax mean?
The portion of income tax expense that will be paid or recovered in future years due to timing differences.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.